Nuvation Bio posts corporate presentation highlighting IBTROZI ROS1 lung cancer franchise
NUVB•Corporate presentation highlights IBTROZI and pipeline
Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, cleared for advanced ROS1+ NSCLC in the U.S., Japan, China.
- U.S. launch metrics through June 30, 2026: about 760 new patient starts, USD 66 million net product revenue.
- Cash, cash equivalents, marketable securities of USD 661 million as of June 30, 2026; path to profitability without additional funding.
- Safusidenib positioned as a brain-penetrant IDH1 inhibitor; pivotal SIGMA study enrolling in high-risk astrocytoma, separate grade 2 phase 3 planned outside U.S.
- Drug-Drug Conjugate platform remains preclinical; candidates under evaluation for solid tumors.
